1 Epidemiology of Hepatocellular Carcinoma

Donna L. White, PhD, MPH, Amir Firozi, MD, and Hashem B. El-Serag, MD, MPH

CONTENTS

ABSTRACT

Hepatocellular carcinoma (HCC) affects more than half a million individuals per year worldwide. It is a largely preventable disease. Most cases are related to hepatitis B virus infection in sub-Saharan Africa and Eastern Asia (except Japan). Hepatitis C virus has emerged as an important cause of HCC particularly in North America and some parts of Europe, where a recent sharp increase in HCC has been reported. There is growing evidence of an association between obesity and diabetes and increased risk of HCC; however, the causal link is still unclear. The striking geographic and racial variations in the occurrence of HCC are partly explained by the distribution of HBV and HCV infections. Additional established risk factors for HCC include older age, male sex, heavy alcohol intake, aflatoxin exposure, iron overload related to hemochromatosis, and possibly tobacco smoking. The

B.I. Carr (ed.), *Hepatocellular Carcinoma*, Current Clinical Oncology
DOI 10.1007/978-1-60327-376-3_1

role of diet except for alcohol drinking and aflatoxin contamination in the etiology of HCC in human populations is largely unknown. Host genetic factors are being examined but definitive data are lacking. Most of these risk factors operate by promoting the development of cirrhosis which is present in most HCC cases. The annual risk of HCC in cirrhosis ranges between 1 and 7%. This review discusses in detail the epidemiology of HCC from a global perspective.

Key Words: Hepatitis C; hepatitis B; cirrhosis; incidence; prevalence; risk; genetic association; coffee; insulin resistance; liver cancer; epidemiology; determinants; risk factors

1. GLOBAL INCIDENCE OF HEPATOCELLULAR CARCINOMA

1.1. Overview

Primary liver cancer is the fifth most common cancer worldwide and the third most common cause of cancer mortality *(1)*. Globally, over 560,000 people develop liver cancer each year and an almost equal number, 550,000, die of it. Liver cancer burden, however, is not evenly distributed throughout the world (Fig. 1). Most HCC cases (>80%) occur in either sub-Saharan Africa or in Eastern Asia. China alone accounts for more than 50% of the world's cases (age-standardized incidence rate (ASR) male: 35.2/100,000; female: 13.3/100,000). Other high-rate (>20/100,000) areas include Senegal (male: 28.47/100,000; female: 12.2/100,000), The Gambia (male: 39.67/100,000; female: 14.6/100,000), and South Korea (male: 48.8/100,000; female: 11.6/100,000).

North and South America, Northern Europe, and Oceania are low-rate (< 5.0/100,000) areas for liver cancer among most populations. Typical incidence rates in these areas are those of the United States (male: 4.21/100,000; female: 1.74/100,000), Canada (male: 3.2/100,000; female: 1.1/100,000), Colombia (male: 2.2/100,000; female: 2.0/100,000), the United Kingdom (male: 2.2/100,000; female: 1.1/100,000), and Australia (male: 3.6/100,000; female: 1.0/100,000). Southern European countries, typified by rates in Spain (male: 7.5/100,000; female: 2.4/100,000), Italy (male: 13.5/100,000; female: 4.6/100,000), and Greece (male: 12.1/100,000; female: 4.6/100,000), are of medium rate (5.0–20.0/100,000) *(2)*.

HCC accounts for between 85 and 90% of primary liver cancer. One noteworthy exception is the Khon Kaen region of Thailand, which has one of the world's highest rates of liver cancer ($ASR_{1993–1997}$ male: 88.0/100,000; female: 35.4/100,000) *(3)*. However, due to endemic infestation with liver



Fig. 1. Regional variations in the incidence rates of hepatocellular carcinoma categorized by age-adjusted incidence rates.

flukes, the major type of liver cancer in this region is intrahepatic cholangiocarcinoma rather than HCC *(4)*.

Encouraging trends in liver cancer incidence have been seen in some of these high-rate areas *(5)*. Between 1978–1982 and 1993–1997, decreases in incidence were reported among Chinese populations in Hong Kong, Shanghai, and Singapore *(3)*. In addition to these areas, Japan also began to experience declines in incidence rates among males for the first time between 1993 and 1997 (Fig. 2).

Many high-rate Asian countries now vaccinate all newborns against HBV and the effect on HCC rates has already become apparent. In Taiwan, where national newborn vaccination began in 1984, HCC rates among children aged 6–14 years declined significantly from 0.70/100,000 in 1981–1986 to 0.36/100,000 in 1990–1994 *(6)*. It is too soon yet for HBV vaccination to have had an effect on adult rates, but other public health measures may have contributed to declines in HCC incidence in high-risk areas of China. A Chinese government program started in the late 1980s to shift the staple diet of the Jiangsu Province from corn to rice may have limited exposure to known hepatocarcinogen aflatoxin B1 (AFB1) in this area *(7)*. Similarly, another Chinese public health campaign initiated in the early 1970s to encourage drinking of well water rather than pond- or ditch water may have decreased



Fig. 2. Recent changes in the incidence of HCC. The incidence of HCC has been declining in some "high-incidence" areas, such as China and Hong Kong. On the other hand, HCC incidence in several "low and intermediate incidence" areas has been increasing. Modified from McGlynn et al. *(5)*.

consumption of microcystins, cyanobacteria-produced compounds demonstrated to be hepatocarcinogenic in experimental animals.

In contrast, registries in a number of low-rate areas reported increases in HCC incidence between 1978–1982 and 1993–1997. Included among these registries are those in the United States, the United Kingdom, and Australia. Reasons for both the decreased incidence in high-rate areas and the increased incidence in low-rate areas are not yet clear, suggesting that each area will be an important case study. It has been widely hypothesized, however, that increased incidence in low-rate areas may be related to greater prevalence of HCV infection within these areas.

1.2. Race/Ethnicity

HCC incidence rates also vary greatly among different populations living in the same region. For example, ethnic Indian, Chinese, and Malay populations of Singapore had age-adjusted rates ranging from 21.21/100,000 among Chinese males to 7.86/100,000 among Indian males between 1993 and 1997 *(3)*. The comparable rates for females were 5.13/100,000 among ethnic Chinese and 1.77/100,000 among ethnic Indians. Another example is the United States where, at all ages and among both genders, HCC rates are two times higher in Asians than in African-Americans, which are themselves two times higher than those in whites. The reason(s) for this interethnic

variability likely include differences in prevalence and acquisition time of major risk factors for liver disease and HCC.

1.3. Gender

In almost all populations, males have higher liver cancer rates than females, with male:female ratios usually averaging between 2:1 and 4:1. At present, the largest discrepancies in rates (>4:1) are found in medium-risk European populations. Typical among these ratios are those reported from Geneva, Switzerland (4.1:1) and Varese, Italy (5.1:1). Among 10 French registries listed in volume VIII of *Cancer in Five Continents*, nine report male:female ratios >5:1. In contrast, typical ratios currently seen in high-risk populations are those of Qidong, China (3.2:1); Osaka, Japan (3.7:1); The Gambia (2.8:1); and Harare, Zimbabwe (2.4:1). Registries in Central and South America report some of the lowest sex ratios for liver cancer. Typical ratios in these regions are reported by Colombia (1.2:1) and Costa Rica (1.6:1).

The reasons for higher rates of liver cancer in males may relate to gender-specific differences in exposure to risk factors. Men are more likely to be infected with HBV and HCV, consume alcohol, smoke cigarettes, and have increased iron stores. Higher levels of androgenic hormones, body mass index, and increased genetic susceptibility may also adversely affect male risk.

1.4. Age

The global age distribution of HCC varies by region, incidence rate, gender and, possibly, by etiology *(3)*. In almost all areas, female rates peak in the age group 5 years older than the peak age group for males. In low-risk populations (e.g., the United States, Canada, the United Kingdom), the highest age-specific rates occur among persons aged 75 and older. A similar pattern is seen among most high-risk Asian populations (e.g., Hong Kong, Shanghai). In contrast, male rates in high-risk African populations (e.g., The Gambia, Mali) tend to peak between ages 60 and 65 before declining; while female rates peak between 65 and 70 before declining. These variable age-specific patterns are likely related to differences in the dominant hepatitis virus in the population, the age at viral infection and the existence of other risk factors. Notably, while most HCV carriers became infected as adults, most HBV carriers became infected at very young ages.

Exceptions to these age patterns occur in Qidong, China, where liver cancer rates are among the world's highest. Age-specific incidence rates among males rise until age 45 and then plateau, while among females, rates rise

until age 60 and then plateau. The explanation for these younger peak ages is unclear, but may be due to existence of other hepatocarcinogenic exposures.

1.5. Distribution of Risk Factors

Major risk factors for HCC vary by region. In most high-risk areas, the dominant risk factor is chronic HBV infection. In Asia, HBV infection is largely acquired by maternal–child transmission, while sibling-to-sibling transmission at young ages is more common in Africa. Consumption of aflatoxin B_1-contaminated foodstuffs is the other major HCC risk factor in most high-rate areas.

Unlike the rest of Asia, the dominant hepatitis virus in Japan is hepatitis C (HCV). HCV began to circulate in Japan shortly after World War II *(8)*. Consequently, HCC rates began to sharply increase in the mid-1970s with an anticipated peak in HCV-related HCC rates projected around 2015, though recent data suggests the peak might have already been reached.

In low-rate HCC areas, increasing numbers of persons living with cirrhosis is the likely explanation for rising HCC incidence. This has resulted from a combination of factors including rising incidence of cirrhosis due to HCV and, to a lesser extent, HBV infection, as well as a general improvement in survival among cirrhosis patients. It has been estimated that HCV began to infect large numbers of young adults in North America and South and Central Europe in the 1960s and the 1970s as a result of intravenous drug use *(9)*. The virus then moved into national blood supplies and circulated until a screening test was developed in 1990, after which time rates of new infection dropped dramatically. Currently, it is estimated that HCV-related HCC in low-rate countries will peak around 2010.

1.6. HCC in the United States

Age-adjusted HCC incidence rates increased more than 2-fold between 1985 and 2002 *(10)* (Fig. 3). Average annual, age-adjusted rate of HCC verified by histology or cytology increased from 1.3 per 100,000 during 1978–1980 to 3.3 per 100,000 during 1999–2001 *(11)*. The increase in HCC started in the mid-1980s with greatest proportional increases occurring during the late 1990s. The largest proportional increases occurred among whites (Hispanics and non-Hispanics), while the lowest proportional increases occurred among Asians. The mean age at diagnosis is approximately 65 years, 74% of cases occur in men, and the racial distribution is 48% white, 15% Hispanic, 13% African-American, and 24% other race/ethnicity (predominantly Asian). During recent years as incidence rates increased, the age distribution of HCC patients has shifted toward relatively younger ages, with greatest proportional increases between ages 45 and 60.



Fig. 3. Average yearly, age-adjusted incidence rates for HCC in the United States shown for 3-year intervals between 1975 and 2002. Whites include approximately 25% Hispanic while other race is predominantly Asian (88%).

Four published studies examined secular changes in HCC risk factors in the United States *(12–15)*. Two studies were from large, single referral centers where viral risk factor ascertainment was based on serology findings, while the other two were from national databases in which risk factors were ascertained from ICD-9 codes in billing or discharge records. In all four studies, the greatest proportional increases occurred in HCV-related HCC, while HBV-related HCC had the lowest and most stable rates. Overall, between 15 and 50% of HCC patients in the United States have no established risk factors.

2. RISK FACTORS OF HEPATOCELLULAR CARCINOMA

HCC is unique in that it largely occurs within an established background of chronic liver disease and cirrhosis (~70–90% of all detected HCC cases) (Fig. 4). Major causes of cirrhosis in patients with HCC include hepatitis B, hepatitis C, alcoholic liver disease, and possibly, non-alcoholic steatohepatitis.

2.1. Hepatitis B Virus

Globally, HBV is the most frequent underlying cause of HCC with an estimated 300 million persons with chronic infection worldwide. Case–control studies have demonstrated that chronic HBV carriers have a 5- to 15-fold increased risk of HCC compared to the general population.



Fig. 4. Estimated progression rates to cirrhosis and hepatocellular carcinoma in hepatitis C infection.

The great majority, between 70 and 90%, of HBV-related HCC develops in a background of cirrhosis. HBV DNA is found in the host genome of both infected and malignant hepatic cells. HBV may, therefore, initiate malignant transformation through a direct carcinogenic mechanism by increasing likelihood of viral DNA insertion in or near proto-oncogenes or tumor-suppressor genes. However, despite initial excitement accompanying this discovery, subsequent research has failed to show a unifying mechanism by which integration of HBV DNA leads to HCC.

The increased HCC risk associated with HBV infection particularly applies to areas where HBV is endemic. In these areas, it is usually transmitted from mother to newborn (vertical transmission) and up to 90% of infected persons follow a chronic course. This pattern is different in areas with low-HCC incidence rates where HBV is acquired in adulthood through sexual and parenteral routes (horizontal transmission) with >90% of acute infections resolving spontaneously. The annual HCC incidence in chronic HBV carriers in Asia ranges between 0.4 and 0.6%. This figure is lower in Alaskan natives (0.26%/year) and lowest in Caucasian HBV carriers *(16)*.

Several other factors have been reported to increase HCC risk among HBV carriers including male gender; older age (or longer duration of infection); Asian or African race; cirrhosis; family history of HCC; exposure to aflatoxin, alcohol, or tobacco; or coinfection with HCV or HDV. HCC risk is also increased in patients with higher levels of HBV replication, as indicated by presence of HBeAg and high HBV DNA levels. In addition, it has been suggested in Asian studies that genotype C is associated with more severe liver disease than genotype B *(17)*.

In the natural history of chronic HBV infection, spontaneous or treatment-induced development of antibodies against HBsAg and HBeAg leads to improved clinical outcomes. A meta-analysis of 12 studies with 1,187 patients who received interferon and 665 untreated patients followed for

5 years found lower HCC incidence in treated 1.9% (95% CI 0.8–3.0%) than untreated patients 3.2% (95% CI 1.8–4.5%). However, this difference was not statistically significant *(18)*.

Using sensitive amplification assays, many studies have demonstrated that HBV DNA persists as "occult HBV infection" for decades among persons with serological recovery (HBsAg negative) from acute infection. Occult HBV is associated with anti-HBc and/or anti-HBs *(19)*. However, in a significant proportion of individuals, neither anti-HBc nor anti-HBs can be detected. A single multinational investigation found prevalence of occult HBV in liver tissue to be 11% in Italy, 5–9% in Hong Kong, and 0% in the United Kingdom. Supporting an association with occult HBV, a high proportion of individuals with HCV infection who develop HCC have demonstrable HBV DNA and proteins in their neoplastic and adjacent non-neoplastic liver tissue. However, although some studies have linked development of HCC in individuals with chronic HCV infection to occult HBV, others have not found an association.

2.2. Hepatitis C Virus

Chronic HCV infection is a major risk factor for development of HCC. Markers of HCV infection are found in a variable proportion of HCC cases; for example, 44–66% in Italy, *(20, 21)* 27–58% in France, 60–75% in Spain, and 80–90% in Japan *(8)*. A higher but undefined proportion of HCC patients might have had HCV detected by PCR testing of liver tissue and/or serum, even if antibody to HCV (anti-HCV) was non-detectable. In a meta-analysis of 21 case–control studies in which second-generation enzyme immunoassay tests for anti-HCV were used, HCC risk was increased 17-fold in HCV-infected patients compared with HCV-negative controls (95% CI 14–22) *(22)*.

The likelihood of development of HCC among HCV-infected persons is difficult to determine due to the paucity of adequate long-term cohort studies; however, the best estimate is from 1 to 3% after 30 years (Fig. 5). HCV increases HCC risk by promoting fibrosis and eventually cirrhosis. Once HCV-related cirrhosis is established, HCC develops at an annual rate of 1–4%; though rates up to 7% have been reported in Japan. Rates of cirrhosis 25–30 years post-infection range between 15 and 35% *(23)*. The highest incidence rates were observed in HCV-contaminated blood or blood products recipients (14 and 1 per 1000 person-years for cirrhosis and HCC, respectively) and in hemophiliacs (5 and 0.7 per 1000 person-years). The lowest rates have been reported in women who received a one-time contaminated anti-D immune globulin treatment (1 and 0 per 1000 person-years, respectively).



Fig. 5. Cirrhosis and hepatocellular carcinoma. Explanted liver showing features of cirrhosis and multiple small foci of HCC throughout the liver in a miliary pattern (*arrows*).

In HCV-infected patients, factors related to host and environment/lifestyle appear to be more important than viral factors in determining progression to cirrhosis. These factors include older age, older age at the time of acquisition of infection, male gender, heavy alcohol intake (>50g/day), diabetes, obesity, and coinfection with HIV or HBV *(24)*. There is no strong evidence that HCV viral factors like genotype, viral load, or quasispecies are important in determining the risk of progression to cirrhosis or HCC.

Successful antiviral therapy in patients with HCV-related cirrhosis may reduce future risk of HCC, but the evidence is weak. There is only one prospective, randomized, controlled trial that examined the effects of antiviral therapy on HCC, a Japanese trial in which 100 patients were randomized to receive either 6 million units of interferon alfa thrice weekly for 3–6 months or were followed without treatment *(25)*. After a 2- to 7-year follow-up period, HCC was significantly reduced in the treated (4%) compared to the non-treated control group (38%), a 93% reduction in adjusted risk. However, much of this risk reduction was a result of the unusually high HCC rate among these controls. Other studies, mostly retrospective and non-randomized, suggested moderately decreased HCC risk among HCV-infected patients treated with interferon *(26–37)*.

In general, reported preventive effects of interferon therapy were less marked in European compared to Japanese studies. However, the lack of randomization in most of these studies may exaggerate treatment benefits as it is likely that healthier patients tend to get treated more frequently than those with advanced liver disease (who are known to be more likely to develop HCC). In addition to a role in primary prevention of HCC among HCV-infected patients, a few Japanese reports suggest interferon may also be effective for secondary prevention in individuals who have previously undergone resection for HCC.

2.3. Alcohol

Heavy alcohol intake, defined as ingestion of >50–70 g/day for prolonged periods, is a well-established HCC risk factor. It is unclear whether risk of HCC is significantly altered in those with low or moderate alcohol intake. Although heavy intake is strongly associated with development of cirrhosis, there is little evidence of a direct carcinogenic effect of alcohol otherwise.

There is also evidence for a synergistic effect of heavy alcohol ingestion with HCV or HBV, with these factors presumably operating together to increase HCC risk by more actively promoting cirrhosis. For example, Donato et al. *(22)* reported that among alcohol drinkers, HCC risk increased in a linear fashion with daily intake >60 g. However, with concomitant presence of HCV infection, there was an additional 2-fold increase in HCC risk over that observed with alcohol usage alone (i.e., a positive synergistic effect).

2.4. Aflatoxin

Aflatoxin B_1 (AFB_1) is a mycotoxin produced by the *Aspergillus* fungus. This fungus grows readily on foodstuffs like corn and peanuts stored in warm, damp conditions. Animal experiments demonstrated that AFB_1 is a powerful hepatocarcinogen leading the International Agency for Research on Cancer (IARC) to classify it as carcinogenic *(30)*.

Once ingested, AFB_1 is metabolized to an active intermediate, AFB_1-*exo*-8,9-epoxide, which can bind to DNA and cause damage, including producing a characteristic mutation in the p53 tumor-suppressor gene (p53 249^{ser}) *(29)*. This mutation has been observed in 30–60% of HCC tumors in aflatoxin endemic areas *(27, 36)*.

Strong evidence that AFB_1 is a risk factor for HCC has been supplied by person-specific epidemiological studies performed in the last 15 years. These studies were permitted by development of assays for aflatoxin metabolites in urine, AFB_1-albumin adducts in serum, and detection of a signature aflatoxin DNA mutation in tissues.

Interaction between AFB_1 exposure and chronic HBV infection was revealed in short-term prospective studies in Shanghai, China. Urinary excretion of aflatoxin metabolites increased HCC risk 4-fold while HBV infection increased risk 7-fold. However, individuals who both excreted AFB_1 metabolites and were HBV carriers had a dramatic 60-fold increased risk of HCC *(38)*.

In most areas where AFB_1 exposure is a problem, chronic HBV infection is also highly prevalent. Though HBV vaccination is these areas should be the major preventive tactic, persons already chronically infected will not

benefit from vaccination. However, HBV carriers could benefit by eliminating AFB_1 exposure. Efforts to accomplish this goal in China *(7)* and Africa *(36)* have been launched.

2.5. Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)

Studies in the United States evaluating risk factors for chronic liver disease or HCC have failed to identify HCV, HBV, or heavy alcohol intake in a large proportion of patients (30–40%). It has been suggested that many cryptogenic cirrhosis and HCC cases, in fact, represent more severe forms of non-alcoholic fatty liver disease (NAFLD), namely non-alcoholic steatohepatitis (NASH). Potential risk factors such as diabetes, obesity, and possibly HCV are likely to increase HCC risk at least partly by promoting NAFLD and NASH.

One difficulty in epidemiological studies attempting to elucidate the association between NASH and risk of HCC in humans, however, is that once either cirrhosis or HCC is established, it is difficult to identify pathological features of NASH. Several clinic-based case–control studies have, in fact, indicated that HCC patients with cryptogenic cirrhosis tend to have clinical and demographic features suggestive of NASH (predominance of women, diabetes, obesity) than age- and sex-matched HCC patients of well-defined viral or alcoholic etiology *(2–4)*. For example, Regimbeau et al. examined 210 patients who underwent resection for HCC of whom 18 (8.6%) had no identifiable cause for chronic liver disease and found higher prevalence of obesity (50% vs. 17% vs. 14%) and diabetes (56% vs. 17% vs. 11%) compared to patients with alcoholic and viral hepatitis, respectively *(39)*. Evidence of progression from NAFLD to HCC from prospective studies is scant. There are case reports *(5, 6)* and a small case series describing development of HCC several years following NASH diagnosis *(40)*. In a community-based retrospective cohort study, 420 patients diagnosed with NAFLD in Olmsted County, MN, were followed for a mean duration of 7.6 years. In that study, liver disease was the third leading cause of death (as compared with the 13th leading cause of death in the general Minnesota population) occurring in seven (1.7%) subjects. Twenty-one (5%) patients were diagnosed with cirrhosis of whom two developed HCC *(5, 6, 8)*.

2.6. Diabetes

Diabetes, particularly type II diabetes, has been proposed to be a risk factor for both chronic liver disease and HCC through development of NAFLD and NASH. It is known to contribute significantly to hepatic steatosis *(9, 10)*

with development of increased levels of steatosis associated with more severe necroinflammatory activity *(11, 12)* and fibrosis *(16–18)*. Fibrosis progression rates have also appeared to be higher when marked steatosis was present *(19)*, with some studies suggesting that the increase in steatosis itself may be an indicator of fibrosis progression *(13)*. Additionally, liver disease occurs more frequently in those with more severe metabolic disturbances, with insulin resistance itself demonstrated to increase as liver disease progresses *(20)*.

Several case–control studies from the United States, Greece, Italy, Taiwan, and Japan examined the association between diabetes, mostly type II, and HCC. At least eight studies found a significant positive association between diabetes and HCC, two found a positive association that did not quite reach significance, and one found a significant negative association. A potential bias in cross-sectional and case–control studies, however, is difficulty in discerning temporal relationships between exposures (diabetes) and outcomes (HCC). This problem is relevant in evaluating HCC risk factors because 10–20% of patients with cirrhosis have overt diabetes and a larger percentage have impaired glucose tolerance. Thus, diabetes may also be the result of cirrhosis.

Cohort studies, which are intrinsically better suited to discern temporal relationships between exposure and disease, have also been conducted. All compared HCC incidence in cohorts of diabetic patients to either the expected incidence given HCC rates in the underlying population or the observed HCC incidence among a defined cohort without diabetes *(41)*. Three studies conducted among younger or smaller cohorts found either no or low number of HCC cases. At least four other cohort studies examined large number of patients for relatively long time periods, with three studies finding significantly increased risk of HCC with diabetes (risk ratios ranging between 2 and 3) *(21–23)*. We recently conducted a study of HCC incidence in a large cohort of VA patients ($n = 173{,}643$ with and $n = 650{,}620$ without diabetes). The findings of this study indicate HCC incidence doubled among patients with diabetes and was higher among those with longer duration of follow-up *(41)* (Fig. 7).

While most studies have been conducted in low-HCC rate areas, diabetes has also been found to be a significant risk factor in areas of high HCC incidence like Japan. Further, although other underlying risk factors like HCV may confound the association between diabetes and HCC, they do not seem to fully explain it. Taken together, available data suggest that diabetes is a moderately strong risk factor for HCC *(42)*. However, additional research is needed to more fully examine how any excess risk conveyed by diabetes is mediated by such potentially confounding factors as duration and treatment of diabetes, family history of diabetes, and current and historical levels of obesity and physical activity.

2.7. Obesity

Obesity, especially abdominal obesity, is strongly correlated with insulin resistance and type II diabetes, a state of clinically diagnosable advanced insulin resistance that has itself been associated with HCC risk. Some evidence in support of a direct contribution of obesity-mediated metabolic errors in hepatocarcinogenesis comes from experimental research in a genetically obese ob/ob knockout mouse model of NAFLD that demonstrated hepatic hyperplasia even at very early stages of disease and without evidence of cirrhosis *(25)*.

The effect of obesity on HCC risk has been examined in several cohort studies. In a large prospective cohort study of more than 900,000 individuals from around the United States followed for a 16-year period, liver cancer mortality rates were five times greater among men with the greatest baseline BMI (35–40) compared to those with normal BMI *(43)* (Fig. 6). In the same study, the risk of liver cancer was not as elevated in women with a relative risk of 1.68 (0.93–3.05). Two other population-based cohort studies from Sweden and Denmark found excess HCC risk (elevated relative risk of 2- to 3-fold) in obese men and women compared to those with normal BMI *(44, 45)*. The effects of obesity on HCC risk may vary according to the presence of other underlying risk factors for HCC; however, the data are consistent. In a large prospective cohort study in Taiwan, obesity (BMI 30+) conveyed excess risk of HCC even after controlling for other metabolic risk factors including presence of diabetes mellitus *(26)*. The greatest increase in risk with obesity was observed in the context of HCV infection (HR = 4.10, 95% CI 1.38–12.4). While a 2.4-fold excess risk that approached significance was also observed among persons who were negative for both HBV and HCV infection, obesity conveyed only a very modest and non-significant 1.4-fold excess risk among persons with HBV



Fig. 6. Obesity and liver cancer. In both men and women, a higher body mass index (BMI) is significantly associated with higher rates of death due to cancer of the liver. Modified from Calle et al. *(43)*.

infection. There was, however, evidence of very strong synergism between obesity and diabetes which, when both conditions occurred together, conveyed a 100-fold excess HCC risk with obesity in the context of either HBV or HCV infection. In a retrospective study of over 19,000 registry-listed individuals in the United states with cirrhosis who received a liver transplant, the effect of obesity on HCC risk also varied according to disease etiology *(46)*. Specifically, obesity conveyed strong and significant excess risk of HCC even after controlling for presence of diabetes among transplant recipients with cryptogenic or alcoholic cirrhosis (OR = 11.1, 95% CI 1.5–87.4 and OR = 3.2, 95% CI 1.5–6.6, respectively). However, obesity was not an independent predictor of HCC risk among those with other disease etiologies including HCV or HBV infection, biliary cirrhosis, or autoimmume hepatitis.

Several case–control studies have also evaluated the association between BMI and risk of HCC. In a study in Japan conducted in chronically HCV-infected patients, the incidence of HCC was significantly increased among those with a higher BMI. Further, there was also evidence of a dose-dependent relationship with a significant 1.8-fold excess HCC risk in HCV+ cases who were overweight (BMI 25–<30) that increased to a 3.1-fold excess in those who were obese (BMI 30+) in comparison to lean HCV+ cases *(33)*. Another case–control study conducted in a regional medical center in the United States compared the prevalence of obesity among 70 HCC cases to that observed among 140 age- and gender-matched controls ($n = 70$ with cirrhosis and $n = 70$ without liver disease) *(47)*. HCC cases were significantly more likely to be obese than either patients with cirrhosis or normal controls (OR = 4.3, 95% CI 2.1–8.4 and OR = 47.8, 95% CI 9.6–74.5). Further, there was evidence of significant synergism or particularly increased risk of HCC among those with obesity (BMI 30+) who also had more than 100 drinks and smoked more than 100 cigarettes during their lifetime (OR = 7.4, 95% CI 2.1–14.6). Although this study did not include adjustment for presence of diabetes, the overall prevalence of diabetes was similar among the HCC case, cirrhotic case, and normal control groups.

Taken together the data suggest that obesity conveys excess risk of HCC beyond that conveyed by diabetes. However, the actual magnitude of risk and the specific subgroups of chronic liver disease patients in whom its presence may be most salient in promoting HCC risk varied across studies. Future research with evaluation of additional factors that may influence obesity-mediated risk of HCC including timing and duration of obesity as well as family history of obesity and diabetes may be helpful in identifying subgroups of obese chronic liver disease patients who may particularly benefit from enhanced surveillance and therapeutic interventions.

In conclusion, many developing countries are in the midst of a burgeoning obesity epidemic. This is particularly apparent in the United States where

a recent national study found that 30% of all adults (60+ million) are obese (i.e., BMI 30+) *(48)* and 16% of all children (9+ million) are overweight (i.e., BMI-for-age $\geq$ 95th percentile per CDC Growth Charts) *(49)*. Although the exact magnitude and mechanisms of obesity-mediated HCC risk are currently unknown, even small increases in obesity-mediated risk could translate into a large number of HCC cases.

2.8. Tobacco

The relationship between cigarette smoking and HCC has been examined in more than 50 studies in both low- and high-rate areas. In almost all countries, both positive association and lack of association findings have been reported. Among studies reporting positive associations, several found effects were limited to population subgroups defined by HBV status, HCV status, genetic polymorphism, or other exposure. Taken together, available evidence suggests that any effect of smoking on HCC is likely to be weak and limited to a subset of the general population. However, because two studies conducted exclusively among women reported positive associations, it has been suggested that attributable risk among women may be higher than that in men *(50, 51)*.

2.9. Oral Contraceptives

The association between oral contraceptives use and HCC risk was examined in at least 12 case–control studies ($n = 740$ cases and $n = 5{,}223$ controls) *(52)*. The pooled estimator was OR = 1.43 (95% CI 0.90–2.26, $p = 0.13$). Six studies showed a significant 2- to 20-fold increase in HCC risk with longer durations (>5 years) of oral contraceptives use. Whether newer, low-dose oral contraceptives convey similar potential risks is currently unknown.

2.10. Diet

The role of diet, except for alcohol drinking and aflatoxin contamination, in the etiology of HCC in human populations is largely unknown. Dietary anti-oxidants including selenium as well as retinoic acid and beta-carotene have been shown to inhibit hepatocarcinogenesis in animals. However, epidemiologic data are fairly limited and in some places conflicting. In a cohort study of men in Taiwan, higher baseline levels of serum retinol were associated with a decreased risk of developing HCC in HBV carriers. In the same cohort, a lower vegetable intake was significantly associated with an increased risk of HCC; however, this effect was limited to individuals who

were both chronic hepatitis B carriers and cigarette smokers *(53)*. In a subsequent report from the same cohort, low baseline serum levels of selenium were also predictive of increased HCC risk *(54)*. In another large cohort study in Japan, the only foods whose consumption conveyed significantly decreased risk of HCC in subjects without a known history of liver disease was fish, while the only food that conveyed decreased risk in subjects with a history of liver disease was coffee. Another study among Japanese atomic bomb survivors reported an approximately 50% reduction in HCC risk among those with high consumption of miso soup and tofu, both rich in the antioxidant isoflavones, after adjusting for HBV and HCV viral infections *(55)*.

Several studies performed in Southern Europe, predominantly in Italy, have also evaluated various dietary factors as potential risk or protective factors for HCC. A favorable effect of high intake of specific foods including milk and yogurt, white meats, eggs, and fruits and of selected macronutrients including beta-carotene was reported by a multicenter hospital-based case–control study in Italy *(56)*. A similar inverse association between vegetable and fruit consumption and risk of HCC was also demonstrated in another much smaller case–control study in Italy. On the other hand, a smaller case–control conducted in Athens, Greece, did not support an association between vegetable intake or any other specific foods or nutrients with risk of HCC, with the possible exception of milk/dairy products which conveyed a modestly decreased risk that closely approached significance *(57)*.

Coffee Drinking: One of the most extensively studied dietary factors in relation to HCC risk in human populations is coffee drinking. Several epidemiological studies have previously reported coffee drinking reduces risk of elevated liver enzymes and of cirrhosis, while animal studies suggest that coffee reduces liver carcinogenesis. Further, coffee drinking has also been associated with reduced insulin levels as well as reduced risk of type II diabetes, itself considered to be a risk factor for HCC *(42)*. At least nine epidemiological studies conducted in Japan and Southern Europe specifically evaluated the relationship between coffee consumption and HCC risk. Coffee drinking was associated with reduced HCC risk in at least five case–control studies (25–75% risk reduction with two to four cups of coffee per day as compared to none) *(42, 58–61)*. Three cohort studies have also reported on the association between coffee intake and subsequent risk of HCC *(62–64)*. Of those, two studies showed significant reduction in HCC risk with coffee intake of one or more cups of coffee, and of those, with one further showing a dose–response relationship (20% reduction with one to two cups and 75% reduction with five or more cups) *(63)*. Although the third publication reporting on two cohorts also showed reduced HCC risk with coffee drinking, its findings were only of borderline significance *(62)*. One potential limitation of most of these studies is that they used general

population controls, which may not be the most appropriate comparator group given their low background risk for HCC as well as for chronic liver disease. However, the inverse association between coffee consumption and HCC persisted in the studies that presented results stratified by liver disease *(42, 60, 62, 65)* or used a second control group of patients with liver disease *(61)*. Taken together these data suggest a modest reduction of HCC risk with coffee drinking. However, the specific components of coffee and the exact mechanisms by which they act to reduce HCC risk are not well established.

Overall, there is increasing evidence suggesting that dietary factors may play a role in promoting hepatocarcinogenesis. However, there are important gaps in the epidemiologic literature that limit broad generalizations about the role specific dietary factors may play in HCC risk both within and across populations. First, studies published to date have used a variety of instruments to assess dietary intake. Even with use of validated instruments, there is well-known difficulty in reliably measuring dietary intake which is further complicated by differences in the relevant time period for which dietary intake was assessed. Second, many studies did not adequately account for factors that may confound the relationship between actual and biologically effective intake of specific micro- and macronutrients including obesity and physical activity. Finally, most studies have been performed in Southeast Asian and Southern European populations. It is unclear whether results obtained solely within those populations would generalize to other populations including those of Northern Europe and North America where there are differences in the underlying risk factors for HCC, dietary patterns, and potentially confounding factors like obesity and diabetes.

3. GENETIC EPIDEMIOLOGY OF HCC

Although a very small minority of HCC cases are associated with familial disorders of Mendelian inheritance like hereditary hemachromatosis, alpha-1-antitrypsin deficiency, or porphyrias, epidemiological research has convincingly demonstrated that the great majority of adult-onset HCC cases are sporadic (i.e., have no similarly affected first-degree relative) and that many have at least one established non-genetic risk factor like habitual alcohol abuse or chronic infection with hepatitis B or C viruses. However, most people with these known environmental risk factors for HCC never develop cirrhosis or HCC, while a sizable minority of HCC cases develop among individuals without any known environmental risk factors.

Genetic variation has long been suspected to influence the variable risk for HCC observed both within and across populations. Familial clusters of disease have been observed in HCC in the context of HBV infection *(66, 67)*

as well as among those without established risk factors *(68)*. As most HCC cases are sporadic or have no similarly affected first-degree relative, interest in the role commonly inherited genetic variants may play as potential risk factors for HCC has grown.

Currently, far fewer genetic epidemiological studies have been reported for HCC than for other more common cancers in developed countries, like lung, prostate, or breast cancers. Most studies in area of HCC have been case–control studies conducted in populations with high HCC rate (Asian, African) or medium rate (European). Typically, they have examined only a limited number of polymorphisms within a few genes selected because of (1) their role in the key liver function of detoxification including Phase I and Phase II enzymes like cytochrome P-450s (CYPs), *N*-acetyltransferases (NATs), and glutathione *S*-transferases (GSTs); (2) their role in biological pathways potentially relevant in chronic liver disease and carcinogenesis including inflammatory response (e.g., interleukins (ILs) 1β, IRN) and DNA repair (e.g., XRCC1); or (3) their role in mitigating or exacerbating the effects of exposure to specific etiologic risk factors for HCC like alcohol or aflatoxin (e.g., ADH3, ALDH2, EPHX1).

Results from the genetic epidemiology studies evaluating varied polymorphisms, including CYPs *(69–71)*, NATs *(72, 73)*, GSTs *(74, 75)*, ILs *(76, 77)*, and ALDH2 *(78, 79)*, as risk factors for HCC have largely been equivocal, with findings of a positive association, association only within a limited subset of the population, or no or negative association all reported. The lack of reproducibility is a phenomenon widely reported in the broader field of genetic epidemiology. It has been widely attributed to inadequate sample sizes to reliably detect the likely small effects of common genetic variants on risk, particularly within a background of strong environmental risk factors and with likely polygenic influences on development of disease *(80, 81)*. Furthermore, virtually all of these studies have lacked power to detect interactions; it is estimated that several thousand cases and controls are required to adequately assess the effects of gene–gene or gene–environment interactions. Other contributing factors include population stratification or population-based differences in the relative distribution of alleles (e.g., among different racial groups), use of non-representative control groups, variable genetic penetrance, and potential differences in relevant genes based on underlying etiology of liver disease (e.g., alcohol or hepatitis related).

Given genetic epidemiology studies are often highly underpowered, meta-analysis has been recognized as an important tool to more precisely define the effect of individual polymorphisms on relative risk of disease and to identify potentially important sources of between-study heterogeneity *(82, 83)*. We recently completed a meta-analysis evaluating the effect of the two most frequently evaluated polymorphisms for HCC risk to date,

the dual deletion of GST polymorphisms *GSTM1* ($n = 14$ studies) and *GSTT1* ($n = 13$ studies) *(84)*. Individual studies for both polymorphisms reported variable findings and therefore the observed heterogeneity necessitated use of a random-effects model. Pooled estimators suggested a possible small excess risk with either *GSTM1* or *GSTT1* null genotypes, though findings approached significance only for *GSTT1* ($OR_{GSTM1} = 1.16$, 95% CI 0.89–1.53, $OR_{GSTT1} = 1.19$, 95% CI 0.99–1.44). Exploratory meta-regressions suggested source of the controls was a possible source of observed between-study heterogeneity, with greater risk among hospital-based controls for both polymorphisms. Year of publication was an additional source of between-study heterogeneity for *GSTM1* only. Although overall pooled estimators for *GSTM1* and *GSTT1* suggest a possible small excess of HCC with the null genotype, additional studies with larger samples and conducted in other populations are needed to further clarify the role of both polymorphisms in the etiology of HCC and to investigate gene–environment interaction.

The epidemiologic literature evaluating selected SNPs as HCC risk factors is currently limited to case–control studies of only small to modest size. Therefore, a particularly noteworthy recent advance in the field of genetic epidemiology is the development of large-scale cohorts or DNA "biobank" cohorts that will be prospectively followed for development of disease (e.g., biobanks in the United Kingdom ($n = 500{,}000$) and Mexico ($n = 200{,}000$)) *(85)*. These large-scale genetic cohort studies offer many important advantages over traditional case–control studies including the ability to validly discern temporal relationships between exposure and disease and the availability of an appropriate control group. However, in spite of their impressive sample size, given the rarity of HCC and the considerable latency until



Fig. 7. The cumulative incidence of HCC among veteran patients hospitalized between 1985 and 1990. The study examined 173,463 patients with diabetes and 650,620 without diabetes. No patient had acute or chronic liver disease recorded before, during, or within 1 year of their index hospitalization.

disease onset, they are unlikely to generate enough HCC cases to fully replace genetic case–control and disease-based registry studies.

Overall, as in other areas of genetic epidemiology, results of studies in HCC have fallen short of early expectations that they would rapidly and unequivocally result in identification of genetic variants conveying substantial excess risk of disease and thereby establish the groundwork for effective genetic screening for primary prevention. However, recent identification of genetic risk factors for some chronic diseases such as Alzheimer's disease and breast cancer, development of multidisciplinary efforts to address the considerable complexity in identifying genetic risk factors, and the increasing accessibility to technology to concomitantly evaluate many thousands of SNPs across the genome (i.e., genome-wide association studies) have contributed to a "cautious optimism" *(85)* that genetic epidemiology will ultimately provide important information on etiopathogenesis of many chronic diseases. Efforts within the field of gastroenterology to promote use of best practice in genetic epidemiologic research may facilitate identification of genetic risk factors for particular diseases of interest including HCC *(86)*.

REFERENCES

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2(9): 533–543.
2. Ferlay J BFPPPDM. GLOBOCAN 2000. Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. Lyon, IARCPress. Limited version available from: URL: http://www-dep iarc fr/globocan/globocan htm 2001.
3. Parkin DM WSFJRLYJe. Cancer Incidence in Five Continents, Vol. VIII. Lyon: IARCPress. IARC Scientific Publications No 155 Lyon: IARC Press 2002.
4. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002; 17(10):1049–1055.
5. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF, Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94(2):290–296.
6. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336(26):1855–1859.
7. Yu S. Primary prevention of hepatocellular carcinoma. J Gastoenterol Hepatol 1995; 10:674–682.
8. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002; 62 Suppl 1:8–17.
9. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31(3):777–782.
10. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127(5 Suppl 1):S27–S34.
11. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139(10):817–823.

12. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127(5):1372–1380.
13. El Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160(21):3227–3230.
14. Hassan MM, Frome A, Patt YZ, El Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002; 35(3):266–269.
15. Kulkarni K, Barcak E, El-Serag H, Goodgame R. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 2004; 20(4):445–450.
16. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150(5):1051–1054.
17. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40(4):1207–1209.
18. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34(4):593–602.
19. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2(8):479–486.
20. Fasani P, Sangiovanni A, De Fazio C et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999; 29(6):1704–1707.
21. Stroffolini T, Andreone P, Andriulli A et al. Gross pathologic types of hepatocellular carcinoma in Italy. Oncology 1999; 56(3):189–192.
22. Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155(4):323–331.
23. Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34(4 Pt 1):809–816.
24. Cramp ME. HBV + HCV = HCC? Gut 1999; 45(2):168–169.
25. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346(8982):1051–1055.
26. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998; 351(9115):1535–1539.
27. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350(6317):429–431.
28. Bruno S, Battezzati PM, Bellati G et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001; 34(5):748–755.
29. Garner RC, Miller EC, Miller JA. Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res 1972; 32(10):2058–2066.
30. IARC Monographs. Overall evaluation of carcinogenicity: An updating of IARC monographs volumes 1–42. Suppl. 7. Lyon: IARCPress 1987; 83–87.
31. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29(4):1124–1130.

32. Imai Y, Kawata S, Tamura S et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129(2):94–99.
33. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28(6):1687–1695.
34. Okanoue T, Itoh Y, Minami M et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30(4):653–659.
35. Serfaty L, Aumaitre H, Chazouilleres O et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27(5):1435–1440.
36. Turner PC, Sylla A, Diallo MS, Castegnaro JJ, Hall AJ, Wild CP. The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa. J Gastroenterol Hepatol 2002; 17 Suppl:S441–S448.
37. Valla DC, Chevallier M, Marcellin P et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29(6):1870–1875.
38. Qian GS, Ross RK, Yu MC et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People′s Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3(1):3–10.
39. Regimbeau JM, Colombat M, Mognol P et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10(2 Suppl 1):S69–S73.
40. Shimada M, Hashimoto E, Taniai M et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37(1):154–160.
41. El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126(2):460–468.
42. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4(3):369–380.
43. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348(17):1625–1638.
44. Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A(3):344–350.
45. Wolk A, Gridley G, Svensson M et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12(1):13–21.
46. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36(1):150–155.
47. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42(2):218–224.
48. Prevalence of overweight and obesity among adults with diagnosed diabetes – United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep 2004; 53(45):1066–1068.
49. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 2004; 291(23):2847–2850.
50. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11(4):369–376.

51. Tanaka K, Hirohata T, Fukuda K, Shibata A, Tsukuma H, Hiyama T. Risk factors for hepatocellular carcinoma among Japanese women. Cancer Causes Control 1995; 6(2):91–98.
52. Maheshwari S, Sarraj O, Kramer J, El-Serag HB. Oral contracepatives and the risk of hepatocellular carcinoma. J Hepatol. 2007; 47(4):506–513.
53. Yu MW, Hsieh HH, Pan WH, Yang CS, Chen CJ. Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res 1995; 55(6): 1301–1305.
54. Yu MW, Horng IS, Hsu KH, Chiang YC, Liaw YF, Chen CJ. Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection 26. Am J Epidemiol 1999; 150(4):367–374.
55. Sauvaget C, Nagano J, Hayashi M, Spencer E, Shimizu Y, Allen N. Vegetables and fruit intake and cancer mortality in the Hiroshima/Nagasaki Life Span Study. Br J Cancer 2003; 88(5):689–694.
56. Talamini R, Polesel J, Montella M et al. Food groups and risk of hepatocellular carcinoma: A multicenter case-control study in Italy 6. Int J Cancer 2006; 119(12):2916–2921.
57. Kuper H. Diet and hepatocellular carcinoma: a case-control study in Greece. 2000.
58. Gallus S, Bertuzzi M, Tavani A et al. Does coffee protect against hepatocellular carcinoma? Br J Cancer 2002; 87(9):956–959.
59. Gelatti U, Covolo L, Franceschini M et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005; 42(4):528–534.
60. Ohfuji S, Fukushima W, Tanaka T et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A case-control study. Hepatol Res 2006; 36(3):201–208.
61. Tanaka K, Hara M, Sakamoto T et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci 2007; 98(2):214–218.
62. Shimazu T, Tsubono Y, Kuriyama S et al. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005; 116(1):150–154.
63. Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97(4):293–300.
64. Kurozawa Y, Ogimoto I, Shibata A et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005; 93(5):607–610.
65. Montella M, Polesel J, La VC et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007; 120(7):1555–1559.
66. Yu MW, Chang HC, Liaw YF et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92(14):1159–1164.
67. Yu MW, Chang HC, Chen PJ et al. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 2002; 31(5):1008–1015.
68. Donato F, Gelatti U, Chiesa R et al. A case-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Brescia HCC Study. Cancer Causes Control 1999; 10(5):417–421.
69. Yu MW, Chiu YH, Yang SY et al. Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Br J Cancer 1999; 80(3–4):598–603.

70. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995; 109(4):1266–1273.
71. Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 2000; 53(2):88–93.
72. Yu MW, Pai CI, Yang SY et al. Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. Gut 2000; 47(5):703–709.
73. Gelatti U, Covolo L, Talamini R et al. N-Acetyltransferase-2, glutathione S-transferase M1 and T1 genetic polymorphisms, cigarette smoking and hepatocellular carcinoma: a case-control study. Int J Cancer 2005; 115(2):301–306.
74. Long XD, Ma Y, Wei YP, Deng ZL. The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res 2006; 36(1):48–55.
75. Sun CA, Wang LY, Chen CJ et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis 2001; 22(8):1289–1294.
76. Migita K, Miyazoe S, Maeda Y et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection – association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol 2005; 42(4):505–510.
77. Nieters A, Yuan JM, Sun CL et al. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 2005; 103(4):740–748.
78. Kato S, Tajiri T, Matsukura N et al. Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand J Gastroenterol 2003; 38(8):886–893.
79. Sakamoto T, Hara M, Higaki Y et al. Influence of alcohol consumption and gene polymorphisms of ADH2 and ALDH2 on hepatocellular carcinoma in a Japanese population. Int J Cancer 2006; 118(6):1501–1507.
80. Cordell HJ, Clayton DG. Genetic association studies. Lancet 2005; 366(9491): 1121–1131.
81. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005; 366(9493):1315–1323.
82. Khoury MJ, Little J. Human genome epidemiologic reviews: the beginning of something HuGE. Am J Epidemiol 2000; 151(1):2–3.
83. Little J, Khoury MJ, Bradley L et al. The human genome project is complete. How do we develop a handle for the pump? Am J Epidemiol 2003; 157(8):667–673.
84. White DL, Li D, Nurgelieva Z, El-Serag HB. The glutathione S-transferase variants as possible risk factors for hepatocellular carcinoma: A HuGE systematic review and meta-analysis.
85. Davey SG, Ebrahim S, Lewis S, Hansell AL, Palmer LJ, Burton PR. Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 2005; 366(9495):1484–1498.
86. El-Serag HB, White DL, Mitra N. Genetic association studies: from "searching under the lamppost" to "fishing in the pond". Gastroenterology 2008; 134(3):662–664.